All news

The Spineway Group, a specialist in innovative implants for the treatment of severe spine disorders, was represented at the 39th edition of the Tunisian Orthopedic Society (SOTCOT) Congress, held from June 6 to 8 in Hammamet, Tunisia.

The Spineway Group, a specialist in innovative implants for the treatment of severe spine disorders, announces that it will be a partner of the Société Française de Chirurgie du Rachis (SFCR) Congress, one of the most important spine surgery events in France. The new edition will be held from June 13 to 15, 2024 at the Corum in Montpellier.

The Spineway Group, a specialist in innovative implants for the treatment of severe spine disorders, announces that it trained nearly 30 spine surgeons in the use of its product lines during a series of sessions held in April and May.

Spineway, a specialist in innovative implants for the treatment of severe spine disorders, recorded revenue of €3.1 million in the first quarter of 2024, an increase of 28% compared with the same period in 2023.

The Combined General Meeting (Ordinary and Extraordinary) of Spineway shareholders was held on first notice on Monday, March 25, 2024 at 4:00 p.m. at the company’s registered office, 7 allée Moulin Berger in Ecully (69).

Spineway announces the completion of the reverse stock split by exchanging 1 new share of 4.00 euros par value for 2,000 old shares of 0.002 euro par value. This transaction, which was carried out pursuant to a decision by the Company's shareholders at an Extraordinary General Meeting held on November 10, 2023, took effect on February 27, 2024.

Spineway informs its shareholders that they are invited to attend the Combined General Meeting to be heldon Monday, March 25, 2024 at 16:00 p.m. at the Group's headquarters, 7 allée Moulin Berger in Ecully (69).

The Board of Directors of Spineway, meeting on February 6, 2024 under the chairmanship of Stéphane Le Roux, approved the financial statements for the year ended December 31, 2023.

Spineway recorded revenue of €10.5 million in 2023, an increase of 42% compared with 2022. This growth was driven by the strong sales performance of Distimp products and the consolidation of revenue from Spine Innovations, acquired in July 2022.